Physician profile
Michael J Mcdonnell
NPI 1467436972
$1,438.61
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $33.33 · 2021: $75.61 · 2022: $104 · 2023: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $146.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $384.79 | 2019 | |
| Pfizer INC. | $355.55 | 2019-2021 | |
| Novo Nordisk INC | $211.91 | 2019 | |
| Medtronic, INC. | $127.38 | 2023 | Signia |
| Astrazeneca Pharmaceuticals LP | $76.55 | 2019-2022 | |
| Glaxosmithkline, LLC. | $44.55 | 2019-2021 | |
| Lilly USA, LLC | $43.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $36.10 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $35.16 | 2022 | |
| Amgen INC. | $32.79 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.95 | 2022 | |
| Theratechnologies INC. | $19.36 | 2023 | Trogarzo, Egrifta |
| Sanofi Pasteur INC. | $17.13 | 2019 | |
| Almatica Pharma LLC | $16.62 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcdonnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.